Vitrolife AB | Balance Sheet

Fiscal year is January-December. All values SEK Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
54
108
200
189
396
491
Total Accounts Receivable
67
102
104
134
154
189
Inventories
60
92
102
146
151
161
Other Current Assets
6
7
8
8
10
9
Total Current Assets
187
309
414
477
710
851
Net Property, Plant & Equipment
86
92
90
94
84
94
Total Investments and Advances
5
10
10
9
9
24
Intangible Assets
206
561
516
649
608
728
Total Assets
488
972
1,059
1,250
1,422
1,697
ST Debt & Current Portion LT Debt
-
17
26
12
37
Accounts Payable
16
22
22
24
31
Income Tax Payable
13
33
35
22
18
Other Current Liabilities
55
79
63
76
86
Total Current Liabilities
100
160
131
159
135
Long-Term Debt
-
-
22
60
36
Provision for Risks & Charges
4
4
5
9
7
Deferred Taxes
12
26
12
39
40
Other Liabilities
25
20
-
-
-
Total Liabilities
165
270
214
230
194
Common Equity (Total)
321
701
843
1,018
1,226
Total Shareholders' Equity
321
701
843
1,018
1,226
Total Equity
323
703
845
1,020
1,229
Liabilities & Shareholders' Equity
488
972
1,059
1,250
1,422
Accumulated Minority Interest
2
2
2
2
3

About Vitrolife AB

View Profile
Address
Gustaf Werners Gata 2
Gothenburg VG 421 32
Sweden
Employees -
Website http://www.vitrolife.com
Updated 07/08/2019
Vitrolife AB engages in the development, manufacture, and sale of products and systems for the preparation, cultivation, and storage of human cells, tissue, and organs. It operates through the following geographical segments: EMEA, North and South America, and Asia & Pacific. Its products include FertiRoof, Vitrification, Slow freezing, OVOIL-culture oil, and Follicle aspiration needles.